2. Ra Medical Systems
R&D spending: $2,776,000
Percentage of revenues: 44.4%
2019 overall revenue ranking: 100
Ra Medical Systems dedicated most of its research and development costs to improving its existing applications and technology platforms.
The company said it plans to expand future efforts to include continued enhancements to and cost reductions for DABRA and Pharos.
Ra Medical Systems currently develops excimer lasers to treat vascular and dermatological diseases. The DABRA systems is designed to ablate a channel in occlusive peripheral vascular disease. Pharos is an excimer laser system that is designed to treat psoriasis, vitiligo, atopic dermatitis and leukoderma.